Sevilla

• N-PLUS Recruiting
  2022-502559-69-01 4 2024-07-04 advanced (FIGO stage IIIA, IIIB, IIIC, or IV of the 2014 FIGO classifi
• An International, Prospective, Open-label, Multi-center, Randomized Phase III Study comparing lutetium (177Lu) vipivotide tetraxetan (AAA617 … Recruiting
  2022-502956-29-00 5 2024-07-01 Oligometastatic prostate cancer (OMPC)
• Registry-based randomized trial to determine the role of Oxygen in acute Pulmonary Embolism Recruiting
  2024-511959-18-01 5 2024-07-01 Acute Pulmonary Embolism
• A Phase 2 Study to Evaluate MORF-057 in Adults with Moderately to Severely Active Crohn’s Disease Recruiting
  2023-508158-24-00 4 2024-06-25 Moderately to Severely Active Crohn’s Disease
• Multicentric trial on the use of combined therapy of Thiamine and biotine in patients with Huntington´s disease. Recruiting
  2023-508637-14-00 9 2024-06-06 Huntington´s disease.
• A Phase 1b/2 Study of BGB-11417 as Monotherapy and in Various Combinations with Dexamethasone plus Carfilzomib, Dexamethasone plus Daratumum … Recruiting
  2023-507751-30-00 9 2024-05-27 relapsed or refractory multiple myeloma
• A study of ASP3082 in adults with advanced solid tumors Recruiting
  2022-501590-39-00 1 2024-05-22 Solid Tumor
• A study of the efficacy and safety of belimumab compared to placebo in adults with systemic sclerosis-associated interstitial lung disease. Recruiting
  2023-503219-14-01 10 2024-05-22 systemic sclerosis associated interstitial lung disease
• Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamo … Recruiting
  2023-506308-24-00 10 2024-05-22 Recurrent or metastatic head and neck squamous cell carcinoma
• A study to investigate long-term safety and tolerability of tolebrutinib in participants with multiple sclerosis Recruiting
  2023-503631-18-01 5 2024-05-20 Nervous system diseases
• CHOP PLUS MOSUNETUZUMAB AS FIRST LINE IN PATIENTS WITH RICHTER´S SYNDROME: A PHASE II STUDY OF THE SPANISH GROUP OF CLL (GELLC-9-RICHTER) Recruiting
  2023-505621-13-00 4 2024-05-14 Richter´syndrome
• Study of the Infusion of ARI-0001 Cells in Patients With CD19 + Acute Lymphoid Leukemia Resistant or Refractory to Therapy Recruiting
  2024-513601-31-00 4 2024-05-13 Acute lymphoid leukemia
• A study to see how well KarXT is tolerated and how well tolerated it is when taken for long time in participants with psychosis associated w … Recruiting
  2023-504151-27-00 5 2024-05-09 Psychosis associated with Alzheimer’s Disease
• Locally Advanced or Metastatic Hepatocellular Carcinoma: Dose Optimization, Safety, and Efficacy of Livmoniplimab in Combination with Budiga … Recruiting
  2023-504600-28-00 10 2024-05-09 Metastatic Hepatocellular Carcinoma (HCC)
• A study to extend treatment with JR-141 after completion of Study JR-141-GS31 Recruiting
  2022-503142-41-00 5 2024-05-06 Mucopolysaccharidosis type II
• The NODE-202 Study (Study of Etripamil Nasal Spray in Pediatric Patients) Recruiting
  2022-500319-38-00 4 2024-05-03 Paroxysmal supraventricular tachycardia (PSVT)
• A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezom … Recruiting
  2023-507632-20-00 5 2024-05-01 Multiple Myeloma
• Study to learn about the safety of fazirsiran and if it can help people with alpha-1 antitrypsin liver disease with mild liver scarring (fib … Recruiting
  2023-504198-19-00 5 2024-04-18 Alpha-1 Antitrypsin Deficiency-Associated Liver Disease
• Efficacy and safety of different antimicrobial DURATions for the treatment of Infections associated with Osteosynthesis Material implanted a … Recruiting
  2023-508442-18-00 5 2024-04-14 Patients with an infection of the osteosynthesis material implanted af
• STUDY OF OP-1250 ADMINSTERED AS MONOTHERAPY AND COMPARED TO STANDARD OF CARE FOR THE TREATMENT OF ER+, HER2– ADVANCED OR METASTATIC BREAST C … Recruiting
  2023-505871-63-00 5 2024-04-08 ER+, HER2- metastatic breast cancer following endocrine and CDK 4/6 in
• A Phase IV, Post-Authorization Safety Study to Investigate the Long-Term Safety of lutetium (177Lu) vipivotide tetraxetan in Adult Participa … Recruiting
  2023-503208-94-00 6 2024-04-04 Prostate cancer
• A clinical trial comparing a new treatment (MK-5684) to approved medication for advanced prostate cancer after prior hormonal therapy and ch … Recruiting
  2023-504899-25-00 5 2024-04-04 Metastatic castration resistant prostate cancer
• Phase 3 study of adjuvant V940 and Pembrolizumab in resected Stage II, IIIA, IIIB NSCLC Recruiting
  2023-504923-20-00 5 2024-04-04 Stage II, IIIA, IIIB (N2) Non-small Cell Lung Cancer
• A Global Pivotal Placebo-Controlled Study of LY3537982 in Combination with Pembrolizumab and LY3537982 in Combination with Pembrolizumab, Pe … Recruiting
  2023-503412-33-00 5 2024-03-29 Stage IIIB-IIIC or Stage IV KRAS G12C-mutant non-small cell lung cance

Showing 601–624 of 1,630 trials